Effect of the dual sodium‐glucose co‐transporter‐1 and ‐2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials
Open Access
- 29 November 2023
- journal article
- review article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (2) , 710-720
Abstract
Aim: To investigate the renal safety profile of sotagliflozin, a novel sodium‐glucose co‐transporter‐1 and ‐2 inhibitor, in patients with type 1 diabetes and type 2 diabetes, with or without renal impairment, as well as its efficacy in decreasing the risk of further renal events, with an emphasis on those with previous renal impairment. Methods: Embase, Medline, CENTRAL and Scopus were searched from their inception until 24 April 2023 for randomized controlled trials that reported estimated glomerular filtration rate (eGFR), urinary albumin excretion or composite renal events (CRE). The Cochrane risk of bias 2 tool was used. Mean difference, relative risk (RR) and 95% confidence intervals were estimated (PROSPERO: CRD42023425583). Results: Fourteen studies were included in this review ( n = 17 574 participants; intervention n = 9312, control n = 8262). The median follow‐up was 24.5 (Q1 = 15.25, Q3 = 28) months. Four studies recruited participants with renal impairment; baseline eGFR ranged from 23.8 to 50.5 mL/min/1.73m 2 . The change in eGFR for studies ( n = 6) with a follow‐up of 52 weeks or longer was −1.23 (−1.45, −1.01) mL/min/1.73m 2 . Sotagliflozin did not significantly alter urinary albumin excretion. No change was observed in the risk of CRE ( n = 6 studies; RR = 0.82 [0.61, 1.12]), including in participants with renal impairment. High risk of bias was a limitation of this review. Conclusions: Sotagliflozin did not adversely affect renal function or change the risk of key renal outcomes, including for participants with pre‐existing renal impairment. Therefore, sotagliflozin was safe; however, further research is needed to determine its efficacy in reducing the risk of diabetic kidney disease.Keywords
This publication has 26 references indexed in Scilit:
- Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trialDiabetes, Obesity and Metabolism, 2019
- Knockout of Na+-glucose cotransporter SGLT1 mitigates diabetes-induced upregulation of nitric oxide synthase NOS1 in the macula densa and glomerular hyperfiltrationAmerican Journal of Physiology-Renal Physiology, 2019
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2019
- SGLT1 inhibition: Pros and consEuropean Journal of Pharmacology, 2018
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes MellitusCirculation, 2016
- Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney diseaseNature Reviews Nephrology, 2015
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes MellitusCirculation, 2014
- LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled TrialClinical Pharmacology & Therapeutics, 2012
- Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic ratAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2012